Holen Sie sich die Stockscreener-App
2.43
0.41%
0.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt FBIO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.42
Offen:
$2.42
24-Stunden-Volumen:
370.32K
Relative Volume:
0.40
Marktkapitalisierung:
$78.25M
Einnahmen:
$63.26M
Nettoeinkommen (Verlust:
$-32.92M
KGV:
-20.33
EPS:
-0.1195
Netto-Cashflow:
$-71.34M
1W Leistung:
+5.19%
1M Leistung:
-21.61%
6M Leistung:
-13.83%
1J Leistung:
+59.87%
1-Tages-Spanne:
$2.39
$2.49
1-Wochen-Bereich:
$2.27
$2.49
52-Wochen-Spanne:
$1.45
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Firmenname
Fortress Biotech Inc
Sektor
Branche
Telefon
781-652-4500
Adresse
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.43 | 77.93M | 63.26M | -32.92M | -71.34M | -0.1195 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-15 | Fortgesetzt | ROTH MKM | Buy |
| 2022-08-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-02 | Eingeleitet | The Benchmark Company | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2018-02-28 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-03-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-10-03 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Fortress Biotech Inc Aktie (FBIO) Neueste Nachrichten
Aug Spikes: Is Fortress Biotech Inc part of any ETFPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Growth Value: How does Fortress Biotech Inc score in quality rankingsDay Trade & High Conviction Investment Ideas - baoquankhu1.vn
Sectors Review: Should value investors consider Fortress Biotech Inc2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Liquidity Mapping Around (FBIOP) Price Events - Stock Traders Daily
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Maintains Target Price $4.5 - Moomoo
Institution Moves: Does Fortress Biotech Inc stock benefit from AI growth2026 Volume Leaders & Risk Controlled Daily Trade Plans - baoquankhu1.vn
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fortress Biotech Inc (FBIO) Stock Price, Trades & News - GuruFocus
FBIO PE Ratio & Valuation, Is FBIO Overvalued - Intellectia AI
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
FBIO SEC FilingsFortress Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS - MarketBeat
Fortress Biotech: Q4 Earnings Snapshot - Barchart.com
Fortress Biotech 2025 10-K: Revenue $63.3M, GAAP net loss $(32.9)M - TradingView
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) boosts cash with PRV sale, royalties - Stock Titan
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
Fortress Biotech Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView — Track All Markets
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M - National Today
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital - TipRanks
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale - Stock Titan
Cyprium Therapeutics sells rare disease priority review voucher for $205 million - StreetInsider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes - GlobeNewswire
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Bitget
Why (FBIOP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aug Spikes: How do insiders feel about Fortress Biotech IncFed Meeting & Expert Curated Trade Ideas - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - marketbeat.com
Fortress Biotech Inc Stock: Business Model, Pipeline Progress, and Investor Considerations in Biotec - AD HOC NEWS
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm - AD HOC NEWS
Portfolio Recap: How does Fortress Biotech Inc score in quality rankingsOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Portfolio Shifts: Can Fortress Biotech Inc deliver alphaQuarterly Earnings Summary & Smart Money Movement Alerts - baoquankhu1.vn
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Buyback Watch: How liquid is Fortress Biotech Inc stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A - Stock Titan
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after the market closes on March 25. - 富途牛牛
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview - Minichart
Mustang Bio (NASDAQ: MBIO) details GBM pipeline, Orphan status and cash - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Understanding Momentum Shifts in (FBIOP) - Stock Traders Daily
Macro Review: How do insiders feel about Fortress Biotech IncMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewswire
Quarterly Earnings: Should value investors consider Fortress Biotech Inc2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Fortress Biotech Inc Stock (ISIN: US32015L1035) Faces Short Interest Pressure Amid Biotech Sector Vo - AD HOC NEWS
Finanzdaten der Fortress Biotech Inc-Aktie (FBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):